In person presentation today, Thursday, June 5 th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) As part of the presentation Dr ...
As part of the presentation Dr. Silberman will discuss the Company's drug candidate, TPI 287. TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel (Taxol®) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback